Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
C2n Diagnostics LLC
Headquarters: St. Louis, MO, United States of America
Website: http://www.c2ndiagnostics.com...
Year Founded: 2007
Status: Private
BioCentury | Jul 30, 2024
Product Development
Eisai’s new data provide insight into how to get the most out of anti-amyloid mAbs
Three-year Leqembi readout in tau subgroup may be most impressive amyloid mAb data to date
BioCentury | Nov 22, 2023
Emerging Company Profile
Sunbird: blood-based diagnostics via exosomes and proteases
Singapore-based Sunbird hopes to roll out its exosome-based Alzheimer’s test in 2025
BioCentury | Dec 2, 2022
Discovery & Translation
DNA insertion without breaks; plus diffusion-based approaches to protein design and more
BioCentury’s roundup of translational news
BioCentury | May 5, 2022
Regulation
May 4 Quick Takes: FDA clears Fujirebio’s Alzheimer’s diagnostic
Plus Jazz licenses sleep disorder therapy from Sumitomo and updates from Apnimed, Phathom, AZ, Kezar
BioCentury | Jan 7, 2022
Market Access
Aduhelm’s Medicare judgement day is almost here
CMS generally hews to FDA’s approvals, but Aduhelm could break the mold
BioCentury | Nov 10, 2021
Product Development
Genentech pours cold water on blood test for Alzheimer’s screening
Argues plasma Aβ42/40 falls short as a method for identifying patients for clinical trials
BioCentury | Nov 9, 2021
Product Development
Nov. 8 Quick Takes: McKinsey under House investigation
Plus: AI play DeepCure raises $40M series A, plus FDA approves Azurity’s Eprontia, Liquidia and C2N
BioCentury | Oct 27, 2021
Product Development
Lilly’s plans for differentiating in Alzheimer’s disease
The pharma gives updates on donanemab, announces Phase II miss for tau mAb
BioCentury | Oct 8, 2021
Product Development
Diadem’s prognostic Alzheimer’s blood test bets on p53 biology
The Italian company plans to launch its test as a screening tool late this year
BioCentury | Sep 28, 2021
Product Development
Alzheimer’s blood markers promise new era of clinical trials
Sensitive technologies could relieve dependence on imaging, but agreement on standards will be key
Items per page:
1 - 10 of 27